Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Certara SDR Email:
Why this fails: The prospect is an expert. They've seen this template 1,000 times. There's zero indication you understand their specific situation. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring compliance people" (job postings - everyone sees this)
Start: "Your Phase 2b trial NCT05234567 hits interim analysis on March 15th with 120 patients enrolled" (ClinicalTrials.gov with specific record number and date)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, trial identifiers.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, regulatory precedents already pulled, patterns already identified - whether they buy or not.
These messages demonstrate precise understanding of the prospect's situation and deliver immediate value. Ordered by quality score (highest first).
Identify oncology trials approaching interim analysis dates based on enrollment velocity in ClinicalTrials.gov. Proactively run PBPK simulations for likely dose modification scenarios using published protocol parameters.
Deliver pre-modeled scenarios before the DSMB meets, showing which dose adjustments maintain efficacy while reducing toxicity.
Interim analysis is a high-stakes moment. Most teams scramble to model scenarios AFTER seeing interim data, wasting weeks. By pre-modeling likely scenarios using their published protocol, you're accelerating their decision-making by 4-6 weeks.
The specificity (their exact trial number, actual interim date, quantified benefit like "40% lower toxicity") proves you understand their timeline pressure. This is genuinely helpful whether they hire you or not.
This play requires internal PBPK modeling capability to run simulations using publicly available trial protocols and pharmacology data.
The simulation outputs are proprietary - competitors without Certara's modeling tools cannot replicate this analysis.Target gene therapy developers who have published sequence data (GenBank) but haven't filed INDs yet. Cross-reference with ClinicalTrials.gov to confirm no active trials.
Deliver regulatory precedents: FDA IND reviews where PBPK modeling supported dose justification in toxicology packages for similar AAV programs.
Gene therapy programs get stuck between preclinical completion and IND filing due to dose justification uncertainty. Showing them that FDA specifically cited PBPK modeling in approval letters for similar programs provides a clear regulatory pathway.
Offering the actual IND review summaries and modeling approaches is immediately actionable - they can use these precedents in their own submission whether they hire you or not.
Identify companies with PREA pediatric study commitments approaching deadlines. Analyze their program against recent FDA partial waiver precedents to identify cost reduction opportunities.
Deliver a comparison showing which successful waiver cases match their program profile and the potential to eliminate 1-2 cohorts.
PREA compliance is expensive ($25M-$35M per eliminated cohort). Most teams don't realize FDA is granting partial waivers for programs that demonstrate extrapolation modeling validity.
By mapping their specific program against successful precedents, you're providing a business case they can take to leadership immediately - with or without hiring you.
This play requires analyzing the recipient's specific program details (therapeutic area, patient population, study design) and comparing to FDA waiver precedents.
The program-specific comparison and cost avoidance analysis is proprietary work product.Target first-in-class therapeutic developers with no precedent approval pathway (identified via DrugBank mechanism analysis). Deliver regulatory precedents where quantitative systems pharmacology supported MOA characterization in FDA approval reviews.
First-in-class programs face uncertainty about what FDA expects for nonclinical pharmacology packages. Showing them that 7 recent approvals cited QSP modeling in approval reviews provides a proven regulatory strategy.
Offering the actual FDA approval excerpts and modeling methodologies is immediately valuable - they can use these to design their own IND package.
Target oncology programs with PREA pediatric requirements approaching deadlines. Compile recent FDA and EMA extrapolation acceptances where PBPK modeling justified reduced pediatric cohorts.
Deliver the regulatory decision letters and modeling frameworks showing how similar programs avoided $35M+ in pediatric study costs.
Pediatric oncology trials are extremely expensive and slow to enroll. Showing recent regulatory precedents where extrapolation was accepted provides both a cost justification and a regulatory strategy.
Offering the actual decision letters and modeling frameworks gives them templates they can adapt for their own program - immediate value regardless of purchase.
Target AAV9 gene therapy programs with published sequences but no active INDs. Deliver regulatory precedents showing FDA-approved INDs used PBPK modeling for FIH dose justification in toxicology packages.
Gene therapy dose selection is critical for safety and FDA scrutiny. Showing that 6 recent AAV9 INDs used PBPK modeling - and that FDA cited this modeling in 4 approval letters - provides a proven regulatory pathway.
Offering the IND summaries and dose modeling approaches gives them a template to accelerate their own IND preparation.
Identify oncology trials with specific interim analysis dates in published protocols. Run PBPK simulations for 4 likely dose modification scenarios before the DSMB meets.
Deliver scenario outputs showing maintained efficacy with quantified toxicity reduction for each dose level.
DSMBs need fast turnaround on dose modification analysis. By pre-modeling scenarios using their published protocol data, you're accelerating their decision-making and reducing trial delay risk.
The quantified benefit ("40% lower toxicity") and specific trial number shows you understand their timeline pressure. This is valuable whether they hire you or not.
This play requires internal PBPK modeling capability to simulate dose scenarios using public trial protocols and published pharmacology data.
The scenario simulations are proprietary analysis that competitors without Certara's tools cannot replicate.Target first-in-class programs with novel dual-mechanism inhibitors (no precedent approvals in DrugBank). Map recent FDA approvals that used systems pharmacology modeling to support MOA characterization.
Deliver approval review excerpts showing FDA cited quantitative MOA evidence as supporting approval decisions.
Dual inhibitors face higher regulatory scrutiny about MOA characterization than single-target drugs. Showing 6 recent precedents where systems modeling supported approval provides a validated regulatory pathway.
Offering the FDA approval excerpts and modeling frameworks gives them concrete examples to reference in their own IND/NDA submissions.
Target companies with December 2025 PREA deadlines and 3+ pediatric cohorts required. Pull 3 specific EMA extrapolation acceptances from 2024 for similar oncology programs.
Deliver the regulatory decision summaries showing how PBPK simulation justified reduced cohorts and saved $30M-$60M per program.
PREA deadlines create urgency. Showing 3 recent precedents with specific cost savings gives them both a business case and regulatory pathway to explore extrapolation.
Offering the actual regulatory documents is immediately useful - they can share these with leadership to justify exploring a modeling approach.
Target oncology programs with 3 pediatric studies required by PREA and December 2025 deadlines. Reference specific EMA precedents where extrapolation modeling was accepted for similar programs.
Quantify cost avoidance ($47M) based on public benchmark data for pediatric trial costs.
Pediatric studies are expensive and slow. The specific cost figure ($47M) and recent regulatory precedent (EMA 2024) creates urgency and credibility.
The routing question ("Is anyone exploring extrapolation?") is easy to answer and non-threatening. This surfaces the right internal champion without asking for a meeting.
Identify Phase 2/3 oncology trials with published interim analysis dates approaching. Reference pattern data showing how many similar trials modified dosing post-interim and the resulting timeline delays.
Ask if they have pre-specified dose adjustment criteria to surface DSMB preparedness.
Interim analysis is a high-pressure moment. Knowing their exact trial number and timeline proves you did homework. The pattern data (4 similar trials modified dosing, 9-month delay) creates urgency.
The question about DSMB criteria is easy to answer but might surface a gap in their preparedness - prompting internal conversation.
Target first-in-class programs with Q2 2025 IND filings planned (from pipeline disclosures). Reference FDA rejection pattern from 2024 where insufficient MOA characterization caused IND delays.
Ask if their package includes quantitative systems modeling to surface potential gap.
They've tracked your pipeline timeline and mechanism (IL-23/IL-17). The FDA rejection pattern (3 programs in 2024) creates credible urgency.
The specific gap identified (quantitative MOA characterization) and timing (Q2 2025 filing) makes this timely and relevant. The question is easy to answer but might surface a deficiency.
Identify trials with specific interim dates and review published protocols to confirm lack of pre-specified dose modification criteria. Reference historical pattern of protocol amendment delays.
The specificity (exact date, patient count, protocol gap) shows deep research. The delay risk (11 months for protocol amendments) creates urgency.
The question about contingency scenarios might feel slightly accusatory but surfaces a real preparedness gap.
Track gene therapy sequence publications in GenBank and cross-reference with ClinicalTrials.gov to identify stalled programs. Quantify competitive threat from similar programs that filed INDs.
Publication tracking shows deep research. The competitive threat (4 programs filed INDs, 12-18 month lag) creates urgency.
Manufacturing bottleneck is a common issue (good educated guess) but the question might feel presumptuous. Timeline pressure is legitimate concern.
Identify gene therapy programs with published sequences but no active clinical trials. Reference competitive programs that filed INDs to create urgency about first-mover advantage.
Publication and competitor tracking proves research depth. Competitive threat is real and quantified (12-18 months behind).
Manufacturing bottleneck is common but question could seem presumptuous. Timeline pressure resonates with biotech leadership concerned about market position.
Target first-in-class programs with no direct precedent approvals in DrugBank. Reference 2024 FDA rejections for insufficient MOA characterization to create urgency.
Mechanism specificity (IL-23/IL-17 dual inhibitor) shows research. FDA rejection risk (2 programs in 2024) creates credible threat.
The question identifies the exact problem area (pharmacology package) but could be seen as fear-mongering. Routing question is easy to answer.
Target programs with 3 pediatric cohorts required before December 2025 deadlines. Reference FDA partial waiver precedents from 2024 and quantify cost avoidance opportunity.
Specific deadline and cost estimate create urgency. Waiver precedents (2 programs in 2024) provide actionable pathway.
Question is non-threatening. Cost estimate might be generic industry math but still directionally accurate. Good timing with 12 months to deadline.
Track AAV9-DMD sequence publications and compare to competitive IND filings. Quantify market cap disadvantage from timeline delays.
Competitive intelligence is specific (3 programs, 12-18 month lag). Market cap impact ($200M) might resonate with CSO concerned about valuation.
CMC is common bottleneck. $200M feels like generic industry stat. Could be too aggressive/confrontational for first outreach.
Target dual-mechanism programs with no direct approval precedents. Reference 2024 FDA Clinical Holds for first-in-class programs with insufficient nonclinical data.
Mechanism specificity shows research. Clinical Hold risk (3 programs in 2024) creates credible threat.
Question addresses specific gap (systems pharmacology modeling). Might come across as fear-based. Timeline pressure is real.
Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data to find companies in specific painful situations. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your Phase 2b trial NCT05234567 hits interim analysis on March 15th" instead of "I see you're hiring for clinical roles," you're not another sales email. You're the person who did the homework.
The messages above aren't templates. They're examples of what happens when you combine real data sources with specific situations. Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable public data. Here are the sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| ClinicalTrials.gov API | sponsor, condition, intervention, phase, status, enrollment, study_type | Phase 2/3 oncology trials approaching interim analysis, gene therapy INDs |
| FDA Orphan Drug Designation Database | drug_name, company_name, orphan_designation_date, indication, approval_status | Orphan drug developers with timeline delays |
| FDA Pediatric Labeling Database | product_name, sponsor, indication, pediatric_study_plan, approval_status | PREA pediatric programs approaching deadlines |
| Drugs@FDA Database | drug_name, applicant, active_ingredient, approval_date, application_type | FDA approval timelines, regulatory precedents |
| CMS NME Approval Compilation | nme_name, sponsor, approval_year, therapeutic_class, application_type | First-in-class therapeutic developers |
| DrugBank (NCBI/PubChem) | drug_name, mechanism_of_action, target_proteins, approval_status | Novel MOA characterization, first-in-class programs |
| PubChem BioAssay Database | compound_id, assay_type, target, activity_data, contributor | First-in-class therapeutic discovery data |
| GenBank (NCBI) | sequence_id, organism, gene_name, protein_description, submission_date | Gene therapy and cell therapy developers |